This site is intended for healthcare professionals

Eli Lilly licenses baricitinib to Natco Pharma for Covid-19 and grants six voluntary licence agreements with Indian Pharma companies for the drug.

Read time: 1 mins
Last updated:19th May 2021
Published:19th May 2021
Eli Lilly announced it has signed a voluntary licensing agreement with Natco Pharma to further expedite the availability of baricitinib for COVID-19 patients in India.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest